Source: Eur Respir J 2011; 37: 475
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Galiè N., Hoeper M.M., Gibbs J.S.R., Simonneau G.. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J 2011; 37: 475

Member's Comments

No comment yet.

Related content which might interest you: Lung transplantation for pulmonary arterial hypertension Source: International Congress 2015 – Lung transplantation in the year 2015: current indications and results Year: 2015 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Pulmonary arterial hypertension Source: ISSN=ISSN 1810-6838, ISBN=, page=126 Year: 2005 Pulmonary arterial hypertension Source: Eur Respir Monogr 2013; 62: 70-84 Year: 2013 Pulmonary arterial hypertension Source: International Congress 2018 – State of the art session: Pulmonary vascular diseases Year: 2018 Pulmonary arterial hypertension Source: Breathe 2010; 6: 377-380 Year: 2010 Pulmonary arterial hypertension Source: ISSN=ISSN 1810-6838, ISBN=, page=397 Year: 2007 Pulmonary arterial hypertension Source: Eur Respir Monogr 2014; 66: 232-246 Year: 2014 Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Pregnancy and pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Assessment of simvastatin treatment on pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Endothelium in pulmonary arterial hypertension Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007